Recombinant human LMO1 protein; Source: E. coli derived, PGEX-4T; Tag: GST; Domain: 11-83 aa of BC069793
Conjugate
Unconjugated
Applications
Application Notes
WB: 1:1000-1:6000
General Notes
This product (Catalog No. DPABH-29256) is a rabbit-derived polyclonal antibody raised against human LMO1, targeting the amino acid region 11–83 of the protein. This antibody exhibits cross-reactivity with Human LMO1 from mouse and rat. It has been affinity purified by Protein A. LOM1 (LIM Domain Only 1), as a Protein Coding gene, encodes a cysteine-rich, two LIM domain transcriptional regulator. It may be involved in gene regulation within neural lineage cells potentially by direct DNA binding or by binding to other transcription factors. A chromosomal aberration involving LMO1 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL)(Uniprot). Diseases associated with LMO1 include T-Cell Acute Lymphoblastic Leukemia and Neuroblastoma (PMID:31830377). The downstream of LMO1-regulatory cascade includes a tumor-promoting LIMS1/ILK pathway, which has a potential to be a novel therapeutic target(PMID: 29695398). The molecular weight of LMO1 is 18 kDa. DPABH-29256 is suitable for use in Western blot (WB) (1:1,000–1:6,000) application. DPABH-29256 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
Target
Alternative Names
Cysteine-rich protein TTG-1; LIM domain only protein 1; LMO 1; LMO-1; RBTN1
My Review for Rabbit Anti-Human LMO1 (a.a. 11-83) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.